The implementation of novel collaborative structures for the identification and resolution of barriers to pluripotent stem cell translation

David A Brindley, Anna French, Jane Suh, MacKenna Roberts, Benjamin Davies, Rafael Pinedo-Villanueva, Karolina Wartolowska, Kelly Rooke, Anneke Kramm, Andrew Judge, Mark Morrey, Amit Chandra, Hannah Hurley, Liam Grover, Ian Bingham, Bernard Siegel, Matt S Rattley, R Lee Buckler, David McKeon, Katie KrumholzLilian Hook, Michael May, Sarah Rikabi, Rosie Pigott, Megan Morys, Afsie Sabokbar, Emily Titus, Yacine Laabi, Gilles Lemaitre, Raymond Zahkia, Doug Sipp, Robert Horne, Christopher Bravery, David Williams, Ivan Wall, Evan Y Snyder, Jeffrey M Karp, Richard W Barker, Kim Bure, Andrew J Carr, Brock Reeve

Research output: Contribution to journalArticle

Abstract

Increased global connectivity has catalyzed technological development in almost all industries, in part through the facilitation of novel collaborative structures. Notably, open innovation and crowd-sourcing-of expertise and/or funding-has tremendous potential to increase the efficiency with which biomedical ecosystems interact to deliver safe, efficacious and affordable therapies to patients. Consequently, such practices offer tremendous potential in advancing development of cellular therapies. In this vein, the CASMI Translational Stem Cell Consortium (CTSCC) was formed to unite global thought-leaders, producing academically rigorous and commercially practicable solutions to a range of challenges in pluripotent stem cell translation. Critically, the CTSCC research agenda is defined through continuous consultation with its international funding and research partners. Herein, initial findings for all research focus areas are presented to inform global product development strategies, and to stimulate continued industry interaction around biomanufacturing, strategic partnerships, standards, regulation and intellectual property and clinical adoption.

Original languageEnglish
Pages (from-to)63-72
Number of pages10
JournalStem cells and development
Volume22
Issue numberSuppl 1
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Pluripotent Stem Cells
Crowdsourcing
Industry
Intellectual Property
Stem Cell Research
Translational Medical Research
Research
Ecosystem
Veins
Stem Cells
Referral and Consultation
Therapeutics

Keywords

  • Cell- and Tissue-Based Therapy
  • Humans
  • Intellectual Property
  • Pluripotent Stem Cells
  • Stem Cell Research/legislation & jurisprudence
  • Translational Medical Research/legislation & jurisprudence

Cite this

Brindley, David A ; French, Anna ; Suh, Jane ; Roberts, MacKenna ; Davies, Benjamin ; Pinedo-Villanueva, Rafael ; Wartolowska, Karolina ; Rooke, Kelly ; Kramm, Anneke ; Judge, Andrew ; Morrey, Mark ; Chandra, Amit ; Hurley, Hannah ; Grover, Liam ; Bingham, Ian ; Siegel, Bernard ; Rattley, Matt S ; Buckler, R Lee ; McKeon, David ; Krumholz, Katie ; Hook, Lilian ; May, Michael ; Rikabi, Sarah ; Pigott, Rosie ; Morys, Megan ; Sabokbar, Afsie ; Titus, Emily ; Laabi, Yacine ; Lemaitre, Gilles ; Zahkia, Raymond ; Sipp, Doug ; Horne, Robert ; Bravery, Christopher ; Williams, David ; Wall, Ivan ; Snyder, Evan Y ; Karp, Jeffrey M ; Barker, Richard W ; Bure, Kim ; Carr, Andrew J ; Reeve, Brock. / The implementation of novel collaborative structures for the identification and resolution of barriers to pluripotent stem cell translation. In: Stem cells and development. 2013 ; Vol. 22 , No. Suppl 1. pp. 63-72.
@article{0520e164c6cb487bbd67e5233bbe8d06,
title = "The implementation of novel collaborative structures for the identification and resolution of barriers to pluripotent stem cell translation",
abstract = "Increased global connectivity has catalyzed technological development in almost all industries, in part through the facilitation of novel collaborative structures. Notably, open innovation and crowd-sourcing-of expertise and/or funding-has tremendous potential to increase the efficiency with which biomedical ecosystems interact to deliver safe, efficacious and affordable therapies to patients. Consequently, such practices offer tremendous potential in advancing development of cellular therapies. In this vein, the CASMI Translational Stem Cell Consortium (CTSCC) was formed to unite global thought-leaders, producing academically rigorous and commercially practicable solutions to a range of challenges in pluripotent stem cell translation. Critically, the CTSCC research agenda is defined through continuous consultation with its international funding and research partners. Herein, initial findings for all research focus areas are presented to inform global product development strategies, and to stimulate continued industry interaction around biomanufacturing, strategic partnerships, standards, regulation and intellectual property and clinical adoption.",
keywords = "Cell- and Tissue-Based Therapy, Humans, Intellectual Property, Pluripotent Stem Cells, Stem Cell Research/legislation & jurisprudence, Translational Medical Research/legislation & jurisprudence",
author = "Brindley, {David A} and Anna French and Jane Suh and MacKenna Roberts and Benjamin Davies and Rafael Pinedo-Villanueva and Karolina Wartolowska and Kelly Rooke and Anneke Kramm and Andrew Judge and Mark Morrey and Amit Chandra and Hannah Hurley and Liam Grover and Ian Bingham and Bernard Siegel and Rattley, {Matt S} and Buckler, {R Lee} and David McKeon and Katie Krumholz and Lilian Hook and Michael May and Sarah Rikabi and Rosie Pigott and Megan Morys and Afsie Sabokbar and Emily Titus and Yacine Laabi and Gilles Lemaitre and Raymond Zahkia and Doug Sipp and Robert Horne and Christopher Bravery and David Williams and Ivan Wall and Snyder, {Evan Y} and Karp, {Jeffrey M} and Barker, {Richard W} and Kim Bure and Carr, {Andrew J} and Brock Reeve",
year = "2013",
month = "12",
doi = "10.1089/scd.2013.0403",
language = "English",
volume = "22",
pages = "63--72",
journal = "Stem cells and development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "Suppl 1",

}

Brindley, DA, French, A, Suh, J, Roberts, M, Davies, B, Pinedo-Villanueva, R, Wartolowska, K, Rooke, K, Kramm, A, Judge, A, Morrey, M, Chandra, A, Hurley, H, Grover, L, Bingham, I, Siegel, B, Rattley, MS, Buckler, RL, McKeon, D, Krumholz, K, Hook, L, May, M, Rikabi, S, Pigott, R, Morys, M, Sabokbar, A, Titus, E, Laabi, Y, Lemaitre, G, Zahkia, R, Sipp, D, Horne, R, Bravery, C, Williams, D, Wall, I, Snyder, EY, Karp, JM, Barker, RW, Bure, K, Carr, AJ & Reeve, B 2013, 'The implementation of novel collaborative structures for the identification and resolution of barriers to pluripotent stem cell translation', Stem cells and development, vol. 22 , no. Suppl 1, pp. 63-72. https://doi.org/10.1089/scd.2013.0403

The implementation of novel collaborative structures for the identification and resolution of barriers to pluripotent stem cell translation. / Brindley, David A; French, Anna; Suh, Jane; Roberts, MacKenna; Davies, Benjamin; Pinedo-Villanueva, Rafael; Wartolowska, Karolina; Rooke, Kelly; Kramm, Anneke; Judge, Andrew; Morrey, Mark; Chandra, Amit; Hurley, Hannah; Grover, Liam; Bingham, Ian; Siegel, Bernard; Rattley, Matt S; Buckler, R Lee; McKeon, David; Krumholz, Katie; Hook, Lilian; May, Michael; Rikabi, Sarah; Pigott, Rosie; Morys, Megan; Sabokbar, Afsie; Titus, Emily; Laabi, Yacine; Lemaitre, Gilles; Zahkia, Raymond; Sipp, Doug; Horne, Robert; Bravery, Christopher; Williams, David; Wall, Ivan; Snyder, Evan Y; Karp, Jeffrey M; Barker, Richard W; Bure, Kim; Carr, Andrew J; Reeve, Brock.

In: Stem cells and development, Vol. 22 , No. Suppl 1, 12.2013, p. 63-72.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The implementation of novel collaborative structures for the identification and resolution of barriers to pluripotent stem cell translation

AU - Brindley, David A

AU - French, Anna

AU - Suh, Jane

AU - Roberts, MacKenna

AU - Davies, Benjamin

AU - Pinedo-Villanueva, Rafael

AU - Wartolowska, Karolina

AU - Rooke, Kelly

AU - Kramm, Anneke

AU - Judge, Andrew

AU - Morrey, Mark

AU - Chandra, Amit

AU - Hurley, Hannah

AU - Grover, Liam

AU - Bingham, Ian

AU - Siegel, Bernard

AU - Rattley, Matt S

AU - Buckler, R Lee

AU - McKeon, David

AU - Krumholz, Katie

AU - Hook, Lilian

AU - May, Michael

AU - Rikabi, Sarah

AU - Pigott, Rosie

AU - Morys, Megan

AU - Sabokbar, Afsie

AU - Titus, Emily

AU - Laabi, Yacine

AU - Lemaitre, Gilles

AU - Zahkia, Raymond

AU - Sipp, Doug

AU - Horne, Robert

AU - Bravery, Christopher

AU - Williams, David

AU - Wall, Ivan

AU - Snyder, Evan Y

AU - Karp, Jeffrey M

AU - Barker, Richard W

AU - Bure, Kim

AU - Carr, Andrew J

AU - Reeve, Brock

PY - 2013/12

Y1 - 2013/12

N2 - Increased global connectivity has catalyzed technological development in almost all industries, in part through the facilitation of novel collaborative structures. Notably, open innovation and crowd-sourcing-of expertise and/or funding-has tremendous potential to increase the efficiency with which biomedical ecosystems interact to deliver safe, efficacious and affordable therapies to patients. Consequently, such practices offer tremendous potential in advancing development of cellular therapies. In this vein, the CASMI Translational Stem Cell Consortium (CTSCC) was formed to unite global thought-leaders, producing academically rigorous and commercially practicable solutions to a range of challenges in pluripotent stem cell translation. Critically, the CTSCC research agenda is defined through continuous consultation with its international funding and research partners. Herein, initial findings for all research focus areas are presented to inform global product development strategies, and to stimulate continued industry interaction around biomanufacturing, strategic partnerships, standards, regulation and intellectual property and clinical adoption.

AB - Increased global connectivity has catalyzed technological development in almost all industries, in part through the facilitation of novel collaborative structures. Notably, open innovation and crowd-sourcing-of expertise and/or funding-has tremendous potential to increase the efficiency with which biomedical ecosystems interact to deliver safe, efficacious and affordable therapies to patients. Consequently, such practices offer tremendous potential in advancing development of cellular therapies. In this vein, the CASMI Translational Stem Cell Consortium (CTSCC) was formed to unite global thought-leaders, producing academically rigorous and commercially practicable solutions to a range of challenges in pluripotent stem cell translation. Critically, the CTSCC research agenda is defined through continuous consultation with its international funding and research partners. Herein, initial findings for all research focus areas are presented to inform global product development strategies, and to stimulate continued industry interaction around biomanufacturing, strategic partnerships, standards, regulation and intellectual property and clinical adoption.

KW - Cell- and Tissue-Based Therapy

KW - Humans

KW - Intellectual Property

KW - Pluripotent Stem Cells

KW - Stem Cell Research/legislation & jurisprudence

KW - Translational Medical Research/legislation & jurisprudence

UR - https://www.liebertpub.com/doi/10.1089/scd.2013.0403

U2 - 10.1089/scd.2013.0403

DO - 10.1089/scd.2013.0403

M3 - Article

C2 - 24304079

VL - 22

SP - 63

EP - 72

JO - Stem cells and development

JF - Stem cells and development

SN - 1547-3287

IS - Suppl 1

ER -